Efficacy，safety and cost-effectiveness of edaravone dexborneol and compound porcine cerebroside ganglioside in the treatment of acute ischemic stroke
- VernacularTitle:依达拉奉右莰醇与复方脑肽节苷脂治疗急性缺血性脑卒中的疗效、安全性和经济性
- Author:
Long LI
1
;
Bin WANG
1
;
Zheng QU
2
;
Junrong HUANG
2
Author Information
1. Dept. of Pharmacy，the Second Affiliated Hospital of Mudanjiang Medical University，Heilongjiang Mudanjing 157011，China
2. College of Pharmacy，Mudanjiang Medical University，Heilongjiang Mudanjing 157011，China
- Publication Type:Journal Article
- Keywords:
edaravone dexborneol;
compound porcine cerebroside ganglioside;
neuroprotective agent;
ischemic stroke;
efficacy
- From:
China Pharmacy
2023;34(8):978-982
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVE To evaluate efficacy， safety and cost-effectiveness of edaravone dexborneol and compound porcine cerebroside ganglioside in the treatment of acute ischemic stroke， and to provide decision-making reference for clinical treatment selection. METHODS The medical records of 488 patients with acute ischemic stroke hospitalized from Jan. 2021 to Dec. 2021 were collected and divided into two groups according to the treatment plan， i.e. 268 patients in edaravone dexborneol group， and 220 patients in compound porcine cerebroside ganglioside group. After baseline levels of the two groups were balanced using propensity score matching method， curative effect was evaluated according to the changes of NIHSS scores before and after treatment； the occurrence of adverse drug reactions in patients were collected from the hospital adverse reaction reporting system； from the perspective of China’s health system， the cost-effectiveness of the two options were analyzed， and one-way sensitivity analysis was conducted. RESULTS After the propensity score matching， 125 patients were included in the edaravone dexborneol group and compound porcine cerebroside ganglioside group， respectively. The response rates were 81.6% and 74.4%， respectively， with no significant difference. The average costs were 13 560.30 yuan and 14 958.68 yuan， respectively； the cost of edaravone dexborneol group was lower than that of compound porcine cerebroside ganglioside group. No adverse reaction reporting information was retrieved in both groups. Results of one-way sensitivity analysis showed that other drug costs in compound porcine cerebroside ganglioside group was relatively sensitive parameters. CONCLUSIONS Short-term efficacy and safety of edaravone dexborneol are equivalent to those of compound porcine cerebroside ganglioside in treating acute ischemic stroke. But edaravone dexborneol regimen had lower cost and is a more economical scheme.
